{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:58:57Z","timestamp":1781650737849,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Venetoclax, a BCL-2 inhibitor, is increasingly used off-label in pediatric malignancies, but safety data remain limited. This pharmacovigilance study analyzed 488 pediatric reports from the FDA Adverse Event Reporting System (FAERS) involving neutropenia and infection with venetoclax use. Disproportionately reported events included sepsis, leukopenia\/agranulocytosis, and pseudomembranous colitis. Most cases involved acute myeloid leukemia or myelodysplastic syndromes and combination therapy. Network analysis revealed co-reporting of hematologic and infectious toxicities. These findings emphasize the need for vigilant monitoring and dedicated pediatric studies to guide venetoclax use and improve supportive care strategies in this vulnerable population receiving intensive or multimodal treatments.<\/jats:p>","DOI":"10.1007\/s00277-026-06951-z","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:19:34Z","timestamp":1776989974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neutropenia and infectious events during off-label treatment with venetoclax in children with malignant disease: a pharmacovigilance analysis of FDA adverse event reporting system reports"],"prefix":"10.1007","volume":"105","author":[{"given":"Edoardo","family":"Muratore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Giunchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fusaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Baccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gottardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Masetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"6951_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","volume":"15","author":"GO Nwosu","year":"2024","unstructured":"Nwosu GO, Ross DM, Powell JA, Pitson SM (2024) Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis 15:413. https:\/\/doi.org\/10.1038\/s41419-024-06810-7","journal-title":"Cell Death Dis"},{"key":"6951_CR2","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/bloodadvances.2023012041","volume":"8","author":"R Masetti","year":"2024","unstructured":"Masetti R, Baccelli F, Leardini D, Locatelli F (2024) Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies? Blood Adv 8:3583\u20133595. https:\/\/doi.org\/10.1182\/bloodadvances.2023012041","journal-title":"Blood Adv"},{"key":"6951_CR3","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1182\/bloodadvances.2023010113","volume":"7","author":"R Masetti","year":"2023","unstructured":"Masetti R, Baccelli F, Leardini D et al (2023) Venetoclax-based therapies in pediatric advanced MDS and relapsed\/refractory AML: a multicenter retrospective analysis. Blood Adv 7:4366\u20134370. https:\/\/doi.org\/10.1182\/bloodadvances.2023010113","journal-title":"Blood Adv"},{"key":"6951_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.clinthera.2024.09.008","volume":"46","author":"M Badawi","year":"2024","unstructured":"Badawi M, Gopalakrishnan S, Engelhardt B et al (2024) Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships. Clin Ther 46:759\u2013767. https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.008","journal-title":"Clin Ther"},{"key":"6951_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bjh.19849","volume":"206","author":"S Cousson","year":"2025","unstructured":"Cousson S, Calvo C, Goldwirt L et al (2025) Monocentric experience of venetoclax-based regimen in paediatric refractory and relapsed AML\/MDS. Br J Haematol 206:209\u2013214. https:\/\/doi.org\/10.1111\/bjh.19849","journal-title":"Br J Haematol"},{"key":"6951_CR6","doi-asserted-by":"publisher","unstructured":"Karol SE, Khaw SL, Zwaan CM et al (2025) Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent\/Young Adult Patients With Relapsed\/Refractory Acute Myeloid Leukaemia. Pediatr Blood Cancer 72. https:\/\/doi.org\/10.1002\/pbc.31714","DOI":"10.1002\/pbc.31714"},{"key":"6951_CR7","unstructured":"Research C for, DE (2019) and FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files. FDA"},{"key":"6951_CR8","unstructured":"Fusaroli M, Giunchi V (2024) DiAna. An open-source toolkit for DIsproportionality. ANAlysis and other pharmacovigilance investigations in the FAERS"},{"key":"6951_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/jac\/dkae103","volume":"79","author":"R Lewis","year":"2024","unstructured":"Lewis R, Niazi-Ali S, McIvor A et al (2024) Triazole antifungal drug interactions-practical considerations for excellent prescribing. J Antimicrob Chemother 79:1203\u20131217. https:\/\/doi.org\/10.1093\/jac\/dkae103","journal-title":"J Antimicrob Chemother"},{"key":"6951_CR10","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E et al (2021) Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov 11:1440\u20131453. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1465","journal-title":"Cancer Discov"},{"key":"6951_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","volume":"21","author":"SE Karol","year":"2020","unstructured":"Karol SE, Alexander TB, Budhraja A et al (2020) Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol 21:551\u2013560. https:\/\/doi.org\/10.1016\/S1470-2045(20)30060-7","journal-title":"Lancet Oncol"},{"key":"6951_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A (2013) Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22:57\u201369. https:\/\/doi.org\/10.1177\/0962280211403604","journal-title":"Stat Methods Med Res"},{"key":"6951_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/ejh.70058","volume":"116","author":"E Vigna","year":"2026","unstructured":"Vigna E, Bruzzese A, Martino EA et al (2026) Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents. Eur J Haematol 116:160\u2013168. https:\/\/doi.org\/10.1111\/ejh.70058","journal-title":"Eur J Haematol"},{"key":"6951_CR14","doi-asserted-by":"publisher","first-page":"108412","DOI":"10.1016\/j.ijid.2026.108412","volume":"164","author":"M Bobo","year":"2026","unstructured":"Bobo M, Lefevre L, Mallet-Guy P et al (2026) Infectious events in fit patients with relapsed or refractory acute myeloid leukemia treated with azacitidine-venetoclax or intensive chemotherapy. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 164:108412. https:\/\/doi.org\/10.1016\/j.ijid.2026.108412","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"6951_CR15","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1038\/srep05918","volume":"4","author":"CD van Borkulo","year":"2014","unstructured":"van Borkulo CD, Borsboom D, Epskamp S et al (2014) A new method for constructing networks from binary data. Sci Rep 4:5918. https:\/\/doi.org\/10.1038\/srep05918","journal-title":"Sci Rep"},{"key":"6951_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3758\/s13428-017-0862-1","volume":"50","author":"S Epskamp","year":"2018","unstructured":"Epskamp S, Borsboom D, Fried EI (2018) Estimating psychological networks and their accuracy: A tutorial paper. Behav Res Methods 50:195\u2013212. https:\/\/doi.org\/10.3758\/s13428-017-0862-1","journal-title":"Behav Res Methods"},{"key":"6951_CR17","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s40264-024-01471-z","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Polizzi S, Menestrina L et al (2024) Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System. Drug Saf 47:1275\u20131292. https:\/\/doi.org\/10.1007\/s40264-024-01471-z","journal-title":"Drug Saf"},{"key":"6951_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41698-024-00740-5","volume":"8","author":"X Wen","year":"2024","unstructured":"Wen X, Lu Y, Li Y et al (2024) Remission rate, toxicity and pharmacokinetics of venetoclax-based induction regimens in untreated pediatric acute myeloid leukemia. NPJ Precis Oncol 8:248. https:\/\/doi.org\/10.1038\/s41698-024-00740-5","journal-title":"NPJ Precis Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06951-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06951-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06951-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:38:00Z","timestamp":1781649480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06951-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6951"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06951-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}